Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  HIV Infection

  Free Subscription


02.04.2018

7 AIDS
6 AIDS Res Hum Retroviruses
2 Antivir Ther
1 Br J Dermatol
3 Clin Infect Dis
6 HIV Med
1 Immunology
1 Int J Cancer
5 J Acquir Immune Defic Syndr
1 J Am Acad Dermatol
1 J Infect Dis
3 J Med Virol
5 J Virol
3 JAMA
1 Lancet
2 Lancet HIV
2 Lancet Infect Dis
3 Lancet Respir Med
1 N Engl J Med
2 Pediatr Infect Dis J
3 PLoS Med
21 PLoS One
1 Science
2 Vaccine
1 Virology


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    AIDS

  1. SHI L, Yu L, Zhong D, Gu C, et al
    TMC120 displayed potent cytotoxic effect on human cervical carcinoma through enhancing the polymerization of microtubules.
    AIDS. 2018 Mar 28. doi: 10.1097/QAD.0000000000001808.
    PubMed     Text format     Abstract available

  2. MERCHANTE N, Rodriguez-Arrondo F, Revollo B, Merino E, et al
    Hepatocellular carcinoma after sustained virological response with interferon-free regimens in HIV/HCV-coinfected patients.
    AIDS. 2018 Mar 28. doi: 10.1097/QAD.0000000000001809.
    PubMed     Text format     Abstract available

  3. BASTEN M, Heijne JCM, Geskus R, Daas CD, et al
    Sexual risk behaviour trajectories among men who have sex with menat risk for HIV in Amsterdam, the Netherlands: a 10 year follow-up study.
    AIDS. 2018 Mar 28. doi: 10.1097/QAD.0000000000001803.
    PubMed     Text format     Abstract available

  4. WILKINSON JD, Williams PL, Yu W, Colan SD, et al
    Cardiac and inflammatory biomarkers in perinatally HIV-infected and HIV-exposed uninfected children.
    AIDS. 2018 Mar 28. doi: 10.1097/QAD.0000000000001810.
    PubMed     Text format     Abstract available

  5. PRESTI RM, Handley S, Droit L, Ghannoum M, et al
    Alterations in the oral microbiome in HIV-infected participants after ART administration are influenced by immune status.
    AIDS. 2018 Mar 28. doi: 10.1097/QAD.0000000000001811.
    PubMed     Text format     Abstract available

  6. ROBINSON-PAPP J, Nmashie-Osei A, Pedowitz E, Benn EKT, et al
    Vagal dysfunction and small intestinal bacterial overgrowth: novel pathways to chronic inflammation in HIV.
    AIDS. 2018 Mar 28. doi: 10.1097/QAD.0000000000001802.
    PubMed     Text format     Abstract available

  7. MARCUS JL, Volk JE, Snowden JM
    Concerns about a study on sexually transmitted infections after initiation of HIV preexposure prophylaxis.
    AIDS. 2018;32:955-956.
    PubMed     Text format    


    AIDS Res Hum Retroviruses

  8. KARAMOV E, Epremyan K, Siniavin A, Zhernov Y, et al
    HIV-1 genetic diversity in recently diagnosed infections in Moscow: predominance of A<sub>FSU</sub>, frequent branching in clusters, and circulation of the Iberian subtype G variant.
    AIDS Res Hum Retroviruses. 2018 Mar 27. doi: 10.1089/AID.2018.0055.
    PubMed     Text format     Abstract available

  9. TAGNOUOKAM NGOUPO PA, Sadeuh-Mba SA, De Oliveira F, Ngo-Malabo ET, et al
    Characterization of a new HIV-1 group N isolate originating from a Cameroonian patient.
    AIDS Res Hum Retroviruses. 2018 Mar 25. doi: 10.1089/AID.2018.0015.
    PubMed     Text format     Abstract available

  10. VILLABONA-ARENAS CJ, Eymard-Duvernay S, Aghokeng AF, Guichet E, et al
    Nucleoside Reverse Transcriptase Inhibitors with reduced predicted activity does not impair second-line therapy with Lopinavir/Ritonavir or Darunavir/Ritonavir.
    AIDS Res Hum Retroviruses. 2018 Mar 25. doi: 10.1089/AID.2017.0290.
    PubMed     Text format     Abstract available

  11. CHATTONG S, Chaikomon K, Chaiya T, Tangkosakul T, et al
    Efficient ZFN-mediated stop codon integration into the CCR5 locus in hematopoietic stem cells: a possible source for intra-bone marrow cell transplantation.
    AIDS Res Hum Retroviruses. 2018 Mar 25. doi: 10.1089/AID.2018.0007.
    PubMed     Text format     Abstract available

  12. KHAIRUNISA SQ, Ueda S, Witaningrum AM, Yunifiar M MQ, et al
    Genotypic Characterization of HIV-1 Prevalent in Kepulauan Riau, Indonesia.
    AIDS Res Hum Retroviruses. 2018 Mar 28. doi: 10.1089/AID.2018.0040.
    PubMed     Text format     Abstract available

  13. JIAO Y, Wang Y, Kong D, Wang C, et al
    Characterization of a New HIV-1 CRF01_AE/CRF07_BC Recombinant virus Form Men Who Have Sex with Men in Beijing, China.
    AIDS Res Hum Retroviruses. 2018 Mar 28. doi: 10.1089/AID.2018.0049.
    PubMed     Text format     Abstract available


    Antivir Ther

  14. MERLINI E, Galli L, Tincati C, Cannizzo ES, et al
    Immune activation, inflammation and HIV DNA after 96-weeks of ATV/r monotherapy: a MODAt substudy.
    Antivir Ther. 2018 Mar 28. doi: 10.3851/IMP3234.
    PubMed     Text format    

  15. TEERAANANCHAI S, Kerr SJ, Ruxrungtham K, Avihingsanon A, et al
    Loss to follow-up and associated factors of patients through the National AIDS Program in Thailand.
    Antivir Ther. 2018 Mar 27. doi: 10.3851/IMP3233.
    PubMed     Text format     Abstract available


    Br J Dermatol

  16. MADDY AJ, Lee EE, Maderal AD, Wang RC, et al
    A case of disseminated follicular spicules in human immunodeficiency virus-associated follicular syndrome in the absence of the seven known human polyomaviruses, suggesting that this disorder is distinct from trichodysplasia spinulosa.
    Br J Dermatol. 2018 Mar 24. doi: 10.1111/bjd.16562.
    PubMed     Text format     Abstract available


    Clin Infect Dis

  17. SHIVAKOTI R, Gupte N, Kumar NP, Kulkarni V, et al
    Intestinal barrier dysfunction and microbial translocation in HIV-infected pregnant women is associated with preterm birth.
    Clin Infect Dis. 2018 Mar 24. pii: 4953365. doi: 10.1093.
    PubMed     Text format     Abstract available

  18. MATHERON S, Descamps D, Gallien S, Besseghir A, et al
    First line raltegravir/emtricitabine/tenofovir combination in HIV-2 infection: phase 2 non-comparative trial (ANRS 159 HIV-2).
    Clin Infect Dis. 2018 Mar 24. pii: 4953343. doi: 10.1093.
    PubMed     Text format     Abstract available

  19. BENSON CA, Andersen JW, Macatangay BJC, Mailliard RB, et al
    Safety and Immunogenicity of Zoster Vaccine Live in HIV-Infected Adults with CD4+ Cell Counts Above 200 Cells/mL Virologically Suppressed on Antiretroviral Therapy.
    Clin Infect Dis. 2018 Mar 26. pii: 4953774. doi: 10.1093.
    PubMed     Text format     Abstract available


    HIV Med

  20. HONGE BL, Jespersen S, Medina C, Te DS, et al
    The challenge of discriminating between HIV-1, HIV-2 and HIV-1/2 dual infections.
    HIV Med. 2018 Mar 24. doi: 10.1111/hiv.12606.
    PubMed     Text format     Abstract available

  21. SEZGIN E, Van Natta ML, Thorne JE, Puhan MA, et al
    Secular trends in opportunistic infections, cancers and mortality in patients with AIDS during the era of modern combination antiretroviral therapy.
    HIV Med. 2018 Mar 24. doi: 10.1111/hiv.12609.
    PubMed     Text format     Abstract available

  22. AEBI-POPP K, Wandeler G, Salazar-Vizcaya L, Metzner K, et al
    Rapid decline of anti-hepatitis C virus (HCV) antibodies following early treatment of incident HCV infections in HIV-infected men who have sex with men.
    HIV Med. 2018 Mar 24. doi: 10.1111/hiv.12602.
    PubMed     Text format     Abstract available

  23. NIMKAR S, Valvi C, Kadam D, Rewari BB, et al
    Loss to follow-up and mortality among HIV-infected adolescents receiving antiretroviral therapy in Pune, India.
    HIV Med. 2018 Mar 24. doi: 10.1111/hiv.12605.
    PubMed     Text format     Abstract available

  24. DAUBY N, Martin C, Hainaut M, Grammens T, et al
    Prevalence and risk factors of measles seronegativity in a cohort of HIV-positive subjects: a retrospective study.
    HIV Med. 2018 Mar 24. doi: 10.1111/hiv.12610.
    PubMed     Text format     Abstract available

  25. BORGHETTI A, Baldin G, Lombardi F, Ciccullo A, et al
    Efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicentre cohort of patients with suppressed HIV-1 replication.
    HIV Med. 2018 Mar 24. doi: 10.1111/hiv.12611.
    PubMed     Text format     Abstract available


    Immunology

  26. GRAY JI, Westerhof LM, MacLeod MKL
    The roles of resident, central and effector memory CD4 T cells in protective immunity following infection or vaccination.
    Immunology. 2018 Mar 23. doi: 10.1111/imm.12929.
    PubMed     Text format     Abstract available


    Int J Cancer

  27. JAQUET A, Tchounga B, Tanon A, Bagny A, et al
    Etiology of hepatocellular carcinoma in West Africa, a case-control study.
    Int J Cancer. 2018 Mar 23. doi: 10.1002/ijc.31393.
    PubMed     Text format     Abstract available


    J Acquir Immune Defic Syndr

  28. FOLDYNA B, Fourman LT, Lu MT, Mueller ME, et al
    Sex Differences in Subclinical Coronary Atherosclerotic Plaque Among Individuals with HIV on Antiretroviral Therapy.
    J Acquir Immune Defic Syndr. 2018 Mar 27. doi: 10.1097/QAI.0000000000001686.
    PubMed     Text format     Abstract available

  29. CANAN CE, Chander G, Monroe AK, Gebo KA, et al
    High-Risk Prescription Opioid use Among People Living with Hiv.
    J Acquir Immune Defic Syndr. 2018 Mar 27. doi: 10.1097/QAI.0000000000001690.
    PubMed     Text format     Abstract available

  30. WAGNER AD, Shah SK, Njuguna IN, Porter KM, et al
    Letter to the Editor: Financial incentives to motivate pediatric HIV testing - assessing the potential for coercion, inducement, and voluntariness.
    J Acquir Immune Defic Syndr. 2018 Mar 27. doi: 10.1097/QAI.0000000000001689.
    PubMed     Text format    

  31. RIVERO-JUAREZ A, Camacho A, Brieva T, Frias M, et al
    Differential timing of cholesterol increase during successful HCV therapy: impact of type of drug combination.
    J Acquir Immune Defic Syndr. 2018 Mar 27. doi: 10.1097/QAI.0000000000001691.
    PubMed     Text format     Abstract available

  32. HUCK DM, Hanna DB, Rubin LH, Maki P, et al
    Carotid Artery Stiffness And Cognitive Decline Among Women With Or At Risk For Hiv Infection.
    J Acquir Immune Defic Syndr. 2018 Mar 23. doi: 10.1097/QAI.0000000000001685.
    PubMed     Text format     Abstract available


    J Am Acad Dermatol

  33. OMLAND SH, Ahlstrom MG, Gerstoft J, Pedersen G, et al
    Risk of skin cancer in HIV-infected patients: a Danish nationwide cohort study.
    J Am Acad Dermatol. 2018 Mar 24. pii: S0190-9622(18)30475.
    PubMed     Text format     Abstract available


    J Infect Dis

  34. SSEMWANGA D, Doria-Rose NA, Redd AD, Shiakolas AR, et al
    Characterization of the Neutralizing Antibody Response in a Case of Genetically Linked HIV Superinfection.
    J Infect Dis. 2018 Mar 22. pii: 4932787. doi: 10.1093.
    PubMed     Text format     Abstract available


    J Med Virol

  35. DENG H, Deng X, Liu Y, Xu Y, et al
    Naturally occurring antiviral drug resistance in HIV patients who are mono-infected or co-infected with HBV or HCV in China.
    J Med Virol. 2018 Mar 24. doi: 10.1002/jmv.25078.
    PubMed     Text format     Abstract available

  36. SINGH R, Mukherjee A, Singla M, Vajpayee M, et al
    Impact of HIV infection and highly active antiretroviral therapy (HAART) on B cell subpopulations in children.
    J Med Virol. 2018 Mar 25. doi: 10.1002/jmv.25074.
    PubMed     Text format     Abstract available

  37. CHEN ZW, Liu L, Chen G, Cheung KW, et al
    Surging HIV-1 CRF07_BC epidemic among recently infected men who have sex with men in Fujian, China.
    J Med Virol. 2018 Mar 25. doi: 10.1002/jmv.25072.
    PubMed     Text format     Abstract available


    J Virol

  38. FETZER I, Gardner MR, Davis-Gardner ME, Prasad NR, et al
    eCD4-Ig variants that more potently neutralize HIV-1.
    J Virol. 2018 Mar 28. pii: JVI.02011-17. doi: 10.1128/JVI.02011.
    PubMed     Text format     Abstract available

  39. STRONGIN Z, Sharaf R, VanBelzen DJ, Jacobson JM, et al
    EFFECT OF SHORT-TERM ART INTERRUPTION ON LEVELS OF INTEGRATED HIV DNA.
    J Virol. 2018 Mar 28. pii: JVI.00285-18. doi: 10.1128/JVI.00285.
    PubMed     Text format     Abstract available

  40. HARKER JA, Wong KA, Dallari S, Bao P, et al
    IL-27R signalling mediates early viral containment and impacts innate and adaptive immunity after chronic lymphocytic choriomeningitis virus infection.
    J Virol. 2018 Mar 28. pii: JVI.02196-17. doi: 10.1128/JVI.02196.
    PubMed     Text format     Abstract available

  41. SALGADO M, Garcia-Minambres A, Dalmau J, Jimenez-Moyano E, et al
    Control of HIV-1 pathogenesis in viremic nonprogressors is independent of Gag-specific CTL responses.
    J Virol. 2018 Mar 28. pii: JVI.00346-18. doi: 10.1128/JVI.00346.
    PubMed     Text format     Abstract available

  42. GARRIDO C, Abad-Fernandez M, Tuyishime M, Pollara JJ, et al
    IL-15 STIMULATED NATURAL KILLER CELLS CLEAR HIV-1 INFECTED CELLS FOLLOWING LATENCY REVERSAL EX VIVO.
    J Virol. 2018 Mar 28. pii: JVI.00235-18. doi: 10.1128/JVI.00235.
    PubMed     Text format     Abstract available


    JAMA

  43. RIDDELL J 4TH, Amico KR, Mayer KH
    HIV Preexposure Prophylaxis: A Review.
    JAMA. 2018;319:1261-1268.
    PubMed     Text format     Abstract available

  44. MITRA S, Florez ID, Tamayo ME, Mbuagbaw L, et al
    Association of Placebo, Indomethacin, Ibuprofen, and Acetaminophen With Closure of Hemodynamically Significant Patent Ductus Arteriosus in Preterm Infants: A Systematic Review and Meta-analysis.
    JAMA. 2018;319:1221-1238.
    PubMed     Text format     Abstract available

  45. EL BCHERAOUI C, Mokdad AH, Dwyer-Lindgren L, Bertozzi-Villa A, et al
    Trends and Patterns of Differences in Infectious Disease Mortality Among US Counties, 1980-2014.
    JAMA. 2018;319:1248-1260.
    PubMed     Text format     Abstract available


    Lancet

  46. GOOSBY E, Jamison D, Swaminathan S, Reid M, et al
    The Lancet Commission on tuberculosis: building a tuberculosis-free world.
    Lancet. 2018;391:1132-1133.
    PubMed     Text format    


    Lancet HIV

  47. CALMY A, Tarr PE
    Will NNRTIs be driving forward again?
    Lancet HIV. 2018 Mar 23. pii: S2352-3018(18)30037.
    PubMed     Text format    

  48. MOLINA JM, Squires K, Sax PE, Cahn P, et al
    Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial.
    Lancet HIV. 2018 Mar 23. pii: S2352-3018(18)30021.
    PubMed     Text format     Abstract available


    Lancet Infect Dis

  49. WALZL G, McNerney R, du Plessis N, Bates M, et al
    Tuberculosis: advances and challenges in development of new diagnostics and biomarkers.
    Lancet Infect Dis. 2018 Mar 23. pii: S1473-3099(18)30111.
    PubMed     Text format     Abstract available

  50. LABORDE-BALEN G, Taverne B, Ndour CT, Kouanfack C, et al
    The fourth HIV epidemic.
    Lancet Infect Dis. 2018;18:379-380.
    PubMed     Text format    


    Lancet Respir Med

  51. PENN-NICHOLSON A, Tameris M, Smit E, Day TA, et al
    Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial.
    Lancet Respir Med. 2018;6:287-298.
    PubMed     Text format     Abstract available

  52. FREGONESE F, Ahuja SD, Akkerman OW, Arakaki-Sanchez D, et al
    Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis.
    Lancet Respir Med. 2018;6:265-275.
    PubMed     Text format     Abstract available

  53. FLOYD K, Glaziou P, Zumla A, Raviglione M, et al
    The global tuberculosis epidemic and progress in care, prevention, and research: an overview in year 3 of the End TB era.
    Lancet Respir Med. 2018;6:299-314.
    PubMed     Text format     Abstract available


    N Engl J Med

  54. YANG YT, Underhill K
    Rethinking Criminalization of HIV Exposure - Lessons from California's New Legislation.
    N Engl J Med. 2018;378:1174-1175.
    PubMed     Text format    


    Pediatr Infect Dis J

  55. NJUGUNA IN, Wagner AD, Omondi VO, Otieno VA, et al
    Financial Incentives for Pediatric HIV Testing in Kenya.
    Pediatr Infect Dis J. 2018 Mar 24. doi: 10.1097/INF.0000000000002035.
    PubMed     Text format     Abstract available

  56. CHI BH, Mutale W, Winston J, Phiri W, et al
    Infant HIV-Free Survival in the Era of Universal Antiretroviral Therapy for Pregnant and Breastfeeding Women: A Community-Based Cohort Study from Rural Zambia.
    Pediatr Infect Dis J. 2018 Mar 27. doi: 10.1097/INF.0000000000001997.
    PubMed     Text format     Abstract available


    PLoS Med

  57. STEKLER JD, Milne R, Payant R, Beck I, et al
    Transmission of HIV-1 drug resistance mutations within partner-pairs: A cross-sectional study of a primary HIV infection cohort.
    PLoS Med. 2018;15:e1002537.
    PubMed     Text format     Abstract available

  58. TYMEJCZYK O, Brazier E, Yiannoutsos C, Wools-Kaloustian K, et al
    HIV treatment eligibility expansion and timely antiretroviral treatment initiation following enrollment in HIV care: A metaregression analysis of programmatic data from 22 countries.
    PLoS Med. 2018;15:e1002534.
    PubMed     Text format     Abstract available

  59. MYER L, Phillips TK, Zerbe A, Brittain K, et al
    Integration of postpartum healthcare services for HIV-infected women and their infants in South Africa: A randomised controlled trial.
    PLoS Med. 2018;15:e1002547.
    PubMed     Text format     Abstract available


    PLoS One

  60. ALLAM O, Samarani S, Mehraj V, Jenabian MA, et al
    HIV induces production of IL-18 from intestinal epithelial cells that increases intestinal permeability and microbial translocation.
    PLoS One. 2018;13:e0194185.
    PubMed     Text format     Abstract available

  61. STOCKBRIDGE EL, Miller TL, Carlson EK, Ho C, et al
    Private sector tuberculosis prevention in the US: Characteristics associated with interferon-gamma release assay or tuberculin skin testing.
    PLoS One. 2018;13:e0193432.
    PubMed     Text format     Abstract available

  62. BINDER K, Krauss S, Bruckmaier G, Marienhagen J, et al
    Visualizing the Bayesian 2-test case: The effect of tree diagrams on medical decision making.
    PLoS One. 2018;13:e0195029.
    PubMed     Text format     Abstract available

  63. GARBER DA, Mitchell J, Adams D, Guenthner P, et al
    Development of a repeat-exposure penile SHIV infection model in macaques to evaluate biomedical preventions against HIV.
    PLoS One. 2018;13:e0194837.
    PubMed     Text format     Abstract available

  64. TRIBUTINO A, Montgomery MC, Bertrand T, Marak T, et al
    Partner notification outcomes after integration of an on-site disease intervention specialist at a sexually transmitted disease clinic.
    PLoS One. 2018;13:e0194041.
    PubMed     Text format     Abstract available

  65. LEBINA L, Milovanovic M, Otwombe K, Abraham P, et al
    PrePex circumcision surveillance: Adverse events and analgesia for device removal.
    PLoS One. 2018;13:e0194271.
    PubMed     Text format     Abstract available

  66. TI L, Socias ME, Wood E, Milloy MJ, et al
    The impact of methadone maintenance therapy on access to regular physician care regarding hepatitis C among people who inject drugs.
    PLoS One. 2018;13:e0194162.
    PubMed     Text format     Abstract available

  67. CHAUHAN R, Datzkiw D, Varma Shrivastav S, Shrivastav A, et al
    In silico identification of microRNAs predicted to regulate N-myristoyltransferase and Methionine Aminopeptidase 2 functions in cancer and infectious diseases.
    PLoS One. 2018;13:e0194612.
    PubMed     Text format     Abstract available

  68. JAN M, Upadhyay C, Alcami Pertejo J, Hioe CE, et al
    Heterogeneity in glycan composition on the surface of HIV-1 envelope determines virus sensitivity to lectins.
    PLoS One. 2018;13:e0194498.
    PubMed     Text format     Abstract available

  69. DERESSA T, Birhan W, Enawgaw B, Abebe M, et al
    Proportion and predictors of transfusion-transmissible infections among blood donors in North Shewa Zone, Central North Ethiopia.
    PLoS One. 2018;13:e0194083.
    PubMed     Text format     Abstract available

  70. BAILEY SL, Bono RS, Nash D, Kimmel AD, et al
    Implementing parallel spreadsheet models for health policy decisions: The impact of unintentional errors on model projections.
    PLoS One. 2018;13:e0194916.
    PubMed     Text format     Abstract available

  71. KIPLAGAT J, Mwangi A, Keter A, Braitstein P, et al
    Retention in care among older adults living with HIV in western Kenya: A retrospective observational cohort study.
    PLoS One. 2018;13:e0194047.
    PubMed     Text format     Abstract available

  72. TERLOYEVA D, Nugmanova Z, Akhmetova G, Akanov A, et al
    Untreated depression among persons living with human immunodeficiency virus in Kazakhstan: A cross-sectional study.
    PLoS One. 2018;13:e0193976.
    PubMed     Text format     Abstract available

  73. SANNA C, Scognamiglio M, Fiorentino A, Corona A, et al
    Prenylated phloroglucinols from Hypericum scruglii, an endemic species of Sardinia (Italy), as new dual HIV-1 inhibitors effective on HIV-1 replication.
    PLoS One. 2018;13:e0195168.
    PubMed     Text format     Abstract available

  74. SPAULDING AC, Drobeniuc A, Frew PM, Lemon TL, et al
    Jail, an unappreciated medical home: Assessing the feasibility of a strengths-based case management intervention to improve the care retention of HIV-infected persons once released from jail.
    PLoS One. 2018;13:e0191643.
    PubMed     Text format     Abstract available

  75. ZIEGLER SJ, Liu C, Landau M, Buzovetsky O, et al
    Insights into DNA substrate selection by APOBEC3G from structural, biochemical, and functional studies.
    PLoS One. 2018;13:e0195048.
    PubMed     Text format     Abstract available

  76. DES JARLAIS DC, Cooper HLF, Arasteh K, Feelemyer J, et al
    Potential geographic "hotspots" for drug-injection related transmission of HIV and HCV and for initiation into injecting drug use in New York City, 2011-2015, with implications for the current opioid epidemic in the US.
    PLoS One. 2018;13:e0194799.
    PubMed     Text format     Abstract available

  77. BURKHOLDER GA, Tamhane AR, Safford MM, Muntner PM, et al
    Racial disparities in the prevalence and control of hypertension among a cohort of HIV-infected patients in the southeastern United States.
    PLoS One. 2018;13:e0194940.
    PubMed     Text format     Abstract available

  78. WAI PP, Shewade HD, Kyaw NTT, Thein S, et al
    Community-based MDR-TB care project improves treatment initiation in patients diagnosed with MDR-TB in Myanmar.
    PLoS One. 2018;13:e0194087.
    PubMed     Text format     Abstract available

  79. DE FRANCESCO D, Wit FW, Cole JH, Kootstra NA, et al
    The 'COmorBidity in Relation to AIDS' (COBRA) cohort: Design, methods and participant characteristics.
    PLoS One. 2018;13:e0191791.
    PubMed     Text format     Abstract available

  80. CHANG AY, Nabbaale J, Nalubwama H, Okello E, et al
    Motivations of women in Uganda living with rheumatic heart disease: A mixed methods study of experiences in stigma, childbearing, anticoagulation, and contraception.
    PLoS One. 2018;13:e0194030.
    PubMed     Text format     Abstract available


    Science

  81. COHEN J
    Concern as HIV prevention strategy languishes.
    Science. 2018;359:1205.
    PubMed     Text format    


    Vaccine

  82. LU PJ, O'Halloran AC, Williams WW, Nelson NP, et al
    Hepatitis B vaccination coverage among adults aged>/=18years traveling to a country of high or intermediate endemicity, United States, 2015.
    Vaccine. 2018 Mar 28. pii: S0264-410X(18)30375.
    PubMed     Text format     Abstract available

  83. PANDEY RK, Ojha R, Aathmanathan VS, Krishnan M, et al
    Immunoinformatics approaches to design a novel multi-epitope subunit vaccine against HIV infection.
    Vaccine. 2018 Mar 20. pii: S0264-410X(18)30387.
    PubMed     Text format     Abstract available


    Virology

  84. ZHANG Y, Lu J, Liu X
    MARCH2 is upregulated in HIV-1 infection and inhibits HIV-1 production through envelope protein translocation or degradation.
    Virology. 2018;518:293-300.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO HIV Infection is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: